Your browser doesn't support javascript.
loading
Unravelling Mechanisms of Doxorubicin-Induced Toxicity in 3D Human Intestinal Organoids.
Rodrigues, Daniela; Coyle, Luke; Füzi, Barbara; Ferreira, Sofia; Jo, Heeseung; Herpers, Bram; Chung, Seung-Wook; Fisher, Ciarán; Kleinjans, Jos C S; Jennen, Danyel; de Kok, Theo M.
Afiliación
  • Rodrigues D; Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • Coyle L; Boehringer Ingelheim International GmbH, Pharmaceuticals Inc., Ridgefield, CT 06877, USA.
  • Füzi B; Department of Pharmaceutical Sciences, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria.
  • Ferreira S; Certara UK Limited, Simcyp Division, Sheffield S1 2BJ, UK.
  • Jo H; Certara UK Limited, Simcyp Division, Sheffield S1 2BJ, UK.
  • Herpers B; Crown Bioscience Netherlands B.V., J.H. Oortweg 21, 2333 CH Leiden, The Netherlands.
  • Chung SW; Boehringer Ingelheim International GmbH, Pharmaceuticals Inc., Ridgefield, CT 06877, USA.
  • Fisher C; Certara UK Limited, Simcyp Division, Sheffield S1 2BJ, UK.
  • Kleinjans JCS; Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • Jennen D; Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • de Kok TM; Department of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, 6229 ER Maastricht, The Netherlands.
Int J Mol Sci ; 23(3)2022 Jan 24.
Article en En | MEDLINE | ID: mdl-35163210

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Intestinos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Intestinos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza